Mirtazapine Accord Healthcare (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic transmission. Its antihistamine activity also contributes to sedation and appetite stimulation.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for mirtazapine in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual action on norepinephrine and serotonin receptors and its antihistaminic effect. It is often chosen for patients who need a sedating antidepressant or who experience insomnia, whereas SSRIs are typically less sedating.

Store the tablets at ambient temperature below 25 °C, in the original packaging, and protect them from moisture and direct sunlight. Do not store in bathrooms or other humid environments to maintain product stability.

Mirtazapine Accord Healthcare is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis or severe neutropenia, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for any signs of infection, liver issues, or changes in mood.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days. Caution is also advised for individuals with known hypersensitivity to mirtazapine, severe hepatic impairment, or those at high risk for suicidal behavior.